ERK2, but not ERK1, mediates acquired and "De novo" resistance to imatinib mesylate: Implication for CML therapy

Clara I. Aceves-Luquero, Anupriya Agarwal, Juan L. Calllejas-Valera, Laura Arias-González, Azucena Esparís-Ogando, Luis del Paso Ovalke, Itxaso Bellón-Echeverria, Miguel A. de la Cruz-Morcillo, Eva M.Galán Moya, Inmaculada Moreno Gimeno, Juan C. Gómez, Michael W. Deininger, Atanasio Pandiella, Ricardo Sánchez Prieto

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Fingerprint Dive into the research topics of 'ERK2, but not ERK1, mediates acquired and "De novo" resistance to imatinib mesylate: Implication for CML therapy'. Together they form a unique fingerprint.

Agriculture & Biology

Chemical Compounds

Medicine & Life Sciences